Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04541251
Status:
UNKNOWN
Last Update Posted:
2021-06-23
First Post:
2020-02-09
Brief Title:
Neoadjuvant Camrelizumab Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Overview
Official Title:
Neoadjuvant Camrelizumab Nab-paclitaxel and Carboplatin in Patients With Stage IB-IIIA Non-small Cell Lung Cancer NANE-LC A Prospective Single-arm Multicenter Phase II Study
Status:
UNKNOWN
Status Verified Date:
2021-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective single-arm multicenter phase II trial enrolled 40 patients who underwent surgery after three cycles of neoadjuvant therapy with camrelizumab nab-paclitaxel and carboplatin The MPR is the primary endpoint and the pCR the complete resection rate the objective response rate the disease-free survival adverse events and quality of life are the secondary endpoints The exploratory endpoints will be used to establish a multiomics artificial intelligence system for neoadjuvant therapy effect prediction and decision-making assistance based on radiomics metabolism genetic and clinic-pathological characteristics and to explore drug resistance mechanisms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None